Best Treatments for CIDP in 2026

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune condition in which the immune system attacks the myelin sheath surrounding peripheral nerves, causing progressive weakness, numbness, and pain in the arms and legs. It affects an estimated approximately 77,000 US adults, with roughly 9,200 new cases diagnosed each year.

The treatment landscape for CIDP has shifted meaningfully since 2024. The FDA approved the first neonatal Fc receptor (FcRn) blocker for CIDP, subcutaneous immunoglobulin options have expanded, and a growing body of evidence supports behavioral and rehabilitative approaches for the pain and fatigue that standard immunotherapies leave unaddressed. Below are the eight treatment categories that define CIDP care in 2026, organized from the most underrecognized to the most established.

Key Takeaways

• CIDP treatments in 2026 span immunotherapy, rehabilitation, behavioral pain management, and newly approved FcRn inhibitors.
• Over 60% of adults with CIDP report chronic pain, yet first-line immunotherapies like IVIg do not directly address pain or fatigue.
• Cognitive behavioral therapy and acceptance-based approaches reduce pain and disability for adults with chronic pain, filling a gap in standard CIDP care.
• Efgartigimod (VYVGART Hytrulo) became the first FDA-approved FcRn blocker for CIDP in June 2024, reducing relapse risk by 61%.
• A coordinated plan combining immunotherapy, physical rehabilitation, and behavioral support may offer the most complete path to improved quality of life.

1. Behavioral Pain Management and Neuroplastic Retraining

Standard CIDP immunotherapies target nerve inflammation. They do not address the chronic pain, fatigue, anxiety, and depression that often persist even when nerve function stabilizes. In a registry of 84 CIDP patients, 62% reported pain, with 29% experiencing neuropathic pain specifically. Depressive symptoms were nearly twice as common in CIDP patients with pain (61%) compared to those without (33%).

Behavioral approaches fill this gap. They target the nervous system's learned pain responses, fear-avoidance cycles, and the emotional burden of living with a chronic neurological condition.

How It Works

Cognitive behavioral therapy (CBT) and acceptance and commitment therapy (ACT) work by retraining how the brain processes and responds to pain signals. CBT helps identify and restructure thought patterns that amplify pain, such as catastrophizing or hypervigilance. ACT builds psychological flexibility, teaching patients to engage with meaningful activities even when pain is present.

These approaches also address the chronic pain and the brain, where prolonged pain shifts neural processing from sensory circuits toward emotional ones. By interrupting fear-pain-avoidance loops, behavioral therapies can reduce both the intensity and the functional impact of CIDP-related pain.

What the Evidence Shows

A Cochrane review of 59 studies and over 5,000 participants found that CBT improves pain and distress for adults with chronic pain, with effects generally maintained at follow-up. The review described CBT as the treatment with the strongest evidence base among psychological approaches.

For acceptance-based therapies, an overview of nine systematic reviews covering 84 meta-analyses found that ACT reduces depression and anxiety at post-treatment. A separate meta-analysis of 21 randomized controlled trials reported medium pain-relief effect sizes, with face-to-face delivery producing stronger results than digital-only formats.

Neuropathic pain guidelines now include recommends psychological support of treatment plans, and a 2026 scoping review confirmed that CBT and mindfulness-based interventions address neuropathic pain inequities.

Who It May Help

Behavioral pain management may benefit adults with CIDP who experience persistent pain, fatigue, or mood symptoms alongside their immunotherapy. It is particularly relevant for patients whose pain and quality-of-life concerns are not addressed by immunotherapy, as these agents have not demonstrated direct effects on pain, stamina, or sensory symptoms.

2. Intravenous Immunoglobulin (IVIg)

IVIg remains the most widely used first-line treatment for CIDP. It works by modulating the immune system with pooled donor antibodies, reducing the autoimmune attack on peripheral nerve myelin. The EAN/PNS guideline recommends IVIg as a first-line induction and maintenance therapy for CIDP.

How It Works

IVIg delivers concentrated immunoglobulin G (IgG) intravenously, typically at a dose of 2 g/kg administered over 2 to 5 days. The infused antibodies interfere with the autoimmune processes damaging peripheral nerves through multiple mechanisms, including blocking harmful antibody activity and modulating inflammatory signaling.

Patients typically receive infusions at a hospital or infusion center, with initial loading doses followed by maintenance infusions every 3 to 4 weeks. Over time, clinicians attempt gradual dose reductions of 15 to 25% every 2 to 3 courses to find the minimum effective dose.

What the Evidence Shows

Multiple randomized controlled trials confirm that IVIg improves disability and nerve conduction in adults with CIDP, with improvements often visible within 6 weeks. Up to 50% of patients eventually achieve treatment-free remission, meaning they can stop IVIg without relapsing.

The recent ADVANCE-CIDP trial provided additional confirmation of IVIg efficacy in patients experiencing CIDP relapse, further supporting its role as a foundational therapy.

However, IVIg does not have demonstrated effects on pain, fatigue, or sensory symptoms. These are frequently cited by patients as major quality-of-life concerns, highlighting the need for complementary approaches.

Who It May Help

IVIg is appropriate for most newly diagnosed adults with CIDP and is often the first treatment clinicians recommend. It is especially useful for patients with progressive motor weakness, as the evidence for motor improvement is strong.

3. Subcutaneous Immunoglobulin (SCIg)

SCIg offers the same immunoglobulin therapy as IVIg but delivered under the skin rather than into a vein. This allows patients to self-administer at home, reducing hospital visits and infusion-day disruption.

How It Works

SCIg is typically administered at a dose of 0.2 g/kg weekly using a small needle placed under the skin of the abdomen or thigh. The infusion takes 30 to 60 minutes and can be done at home after initial training. A newer hyaluronidase-facilitated formulation allows larger volumes per injection site, potentially reducing infusion frequency to every 2 to 4 weeks.

What the Evidence Shows

A systematic review of 50 studies and roughly 1,400 CIDP patients found that SCIg is a viable maintenance alternative to IVIg for many patients. In a 12-month observational study of 62 CIDP patients, 84% continued SCIg treatment with stable clinical outcomes, though 31% needed dose increases during the transition period.

Patient preference data consistently favors SCIg for its convenience. A discrete choice experiment found that patients, caregivers, and physicians all prefer home-based delivery.

Who It May Help

SCIg is a strong option for adults with CIDP who are stable on IVIg and want to reduce infusion-center visits. It may also suit patients who experience systemic side effects from rapid IVIg infusion, since subcutaneous delivery produces steadier antibody levels.

4. Corticosteroids

Corticosteroids were the first treatment identified as effective for CIDP, dating back to 1958. They suppress the overactive immune response that damages peripheral nerve myelin.

How It Works

Two main dosing strategies are used. Pulsed dexamethasone delivers 40 mg orally for 4 consecutive days each month. Alternatively, intravenous methylprednisolone is given at 500 mg daily for 4 days monthly. Daily oral prednisolone (starting at 60 mg and tapering) is a third option, though pulsed regimens are generally preferred.

Pulsed dexamethasone has a more favorable side-effect profile than daily prednisolone, with lower cumulative steroid exposure over the treatment course.

What the Evidence Shows

Corticosteroids achieve a response rate of approximately 61% across regimens, with a 33% probability of reaching long-term remission. A Cochrane review confirmed that corticosteroids produce short-term improvement in CIDP, though the overall evidence base includes limited randomized data.

Corticosteroids may offer longer remission duration than IVIg in certain patients. However, long-term use carries well-documented risks including weight gain, osteoporosis, diabetes, and mood disturbance.

Who It May Help

Corticosteroids are a reasonable first-line option for adults with CIDP, particularly when cost or access limits IVIg availability. They tend to be preferred in patients with sensory-predominant CIDP. Clinicians generally avoid corticosteroids in pure motor CIDP variants, where they may worsen motor symptoms in certain cases.

5. Plasma Exchange (Plasmapheresis)

Plasma exchange physically removes harmful autoantibodies and immune complexes from the blood. It is typically reserved for patients who do not respond adequately to IVIg or corticosteroids.

How It Works

During plasma exchange, blood is drawn from the patient, separated into cells and plasma, and the plasma (containing the pathogenic antibodies) is discarded and replaced with albumin or donor plasma. A standard protocol involves four exchanges over two weeks, followed by maintenance sessions every 2 to 4 weeks based on response.

The procedure typically requires intravenous access through peripheral lines (preferred over central lines to reduce complications) and takes several hours per session.

What the Evidence Shows

A Cochrane review of two randomized controlled trials found that plasma exchange improves disability short-term along with clinical impairment and motor nerve conduction velocity. Between one-third and two-thirds of CIDP patients experience short-term benefit, and over 80% of responders in clinical trials did not require additional therapies.

The EAN/PNS guideline gives its highest-level recommendation for recommends plasma exchange second-line.

Rapid deterioration after treatment is a known limitation, and adverse events related to venous access and hemodynamic shifts are not uncommon.

Who It May Help

Plasma exchange may be appropriate for adults with CIDP who have not responded to IVIg or corticosteroids, or who need rapid symptom stabilization (for example, during a severe relapse). It is less practical as a long-term maintenance strategy due to the need for regular hospital visits and procedural access.

6. Physical Therapy and Rehabilitation

Physical rehabilitation addresses the functional consequences of CIDP, including muscle weakness, balance impairment, reduced endurance, and fatigue. Unlike immunotherapies, rehabilitation directly targets what patients can do in daily life.

How It Works

Effective CIDP rehabilitation combines multiple exercise modalities: resistance training to rebuild strength in weakened limbs, aerobic conditioning for cardiovascular fitness and fatigue reduction, balance exercises to reduce fall risk, and flexibility work. Occupational therapy complements physical therapy by addressing fine motor tasks, adaptive equipment, and managing weakness in daily life.

The key principle is individualization. Overexertion can delay recovery, so the "no pain, no gain" approach does not apply. Supervised, graded programs are preferred.

What the Evidence Shows

A 2025 systematic review of 13 studies found that multicomponent exercise programs improve fatigue and function in adults with CIDP and related conditions. Optimal results were associated with supervised sessions of 45 to 60 minutes, 3 to 4 times per week, for more than 12 weeks. Aerobic training at 65 to 90% of maximum heart rate produced the strongest cardiovascular improvements, with gains of approximately 30% in strength and fitness measures.

Gains tend to diminish after exercise programs are discontinued, reinforcing the need for ongoing physical activity even after symptoms improve.

Who It May Help

Physical therapy is appropriate for virtually all adults with CIDP, regardless of disease stage. It is especially valuable for patients experiencing residual weakness or fatigue despite adequate immunotherapy, and for those returning to work or daily activities after a relapse.

7. Immunosuppressant Medications

Immunosuppressants are typically considered when first-line therapies (IVIg, corticosteroids, plasma exchange) are insufficient or when patients remain dependent on high doses of these treatments. They aim to provide deeper immune suppression to control CIDP long-term.

How It Works

Rituximab, a monoclonal antibody that depletes B cells, is the most commonly used immunosuppressant in refractory CIDP. It is given as 2 g total over 2 weeks or 375 mg/m2 weekly for 4 weeks. Cyclophosphamide, an older alkylating agent, is administered at 1 g/m2 intravenously monthly for up to 6 months. Other agents used in clinical practice include mycophenolate mofetil, azathioprine, and cyclosporine, though evidence for these remains limited to case series and clinical experience.

What the Evidence Shows

Multiple case series report that rituximab achieves response rates of approximately 70% in CIDP patients who are refractory to first-line therapies, with response typically emerging within 2 months. A case series of 15 refractory CIDP patients treated with cyclophosphamide reported 73% complete remission.

It is worth noting that randomized controlled trials of azathioprine, methotrexate, and interferon beta-1a did not demonstrate benefit for CIDP, despite their continued use in clinical practice. An Italian randomized controlled trial evaluating rituximab for CIDP is ongoing and may provide stronger evidence.

Who It May Help

Immunosuppressants are reserved for adults with refractory CIDP who have not responded to at least two first-line therapies, or for patients requiring unacceptably high maintenance doses of IVIg or corticosteroids. These agents carry meaningful side-effect profiles (including infection risk and, for cyclophosphamide, bladder toxicity), so they are used when the potential benefit outweighs these risks.

8. FcRn Inhibitors and Emerging Therapies

The newest class of treatments for CIDP targets the neonatal Fc receptor (FcRn), a protein that recycles immunoglobulin G antibodies and prolongs their lifespan. Blocking FcRn reduces circulating IgG, including the pathogenic autoantibodies that drive CIDP.

How It Works

Efgartigimod alfa and hyaluronidase-qvfc (VYVGART Hytrulo) is administered as a once-weekly subcutaneous injection lasting 30 to 90 seconds. By blocking FcRn, it accelerates the clearance of IgG antibodies from the bloodstream, reducing the autoimmune attack on peripheral nerve myelin. Unlike IVIg (which adds antibodies) or plasma exchange (which removes them mechanically), FcRn inhibitors work at the receptor level to lower total IgG production.

What the Evidence Shows

The FDA approved efgartigimod for CIDP in June 2024, making it the first FcRn blocker for CIDP. The approval was based on the ADHERE trial, which demonstrated a 61% lower relapse risk compared to placebo. After four or more injections, 78% of participants showed improvement as the drug reached full IgG-lowering effect.

The European Medicines Agency (EMA) granted approval in 2025. The drug was generally well tolerated, with mild treatment-related adverse events in the trial.

Several additional FcRn inhibitors are in late-stage clinical trials. Nipocalimab is being evaluated in the ARISE trial with 300 participants, with completion expected in 2027. Batoclimab is under evaluation at two dose levels. Beyond FcRn inhibitors, complement pathway inhibitors (such as SAR445088, an anti-C1s antibody) are in Phase 2 trials, and hematopoietic autologous stem cell transplant has shown 80% five-year remission rate in a prospective study of 66 subjects with severe refractory CIDP.

Who It May Help

Efgartigimod is FDA-approved for adults with CIDP and may be particularly appealing for patients who want a simple weekly injection rather than lengthy IVIg infusions. It is also relevant for patients experiencing side effects from corticosteroids or those who cannot access regular infusion centers. The pipeline therapies may expand options further for refractory cases.

How Lin Health Helps with CIDP

Living with CIDP means managing more than the autoimmune process itself. Pain, fatigue, anxiety, and the emotional weight of a chronic neurological diagnosis are constant companions for many patients, and standard immunotherapies were not designed to address them.

Lin Health's approach is based on findings from research on CBT, ACT, and behavioral pain management. The program specifically targets the nervous system's learned pain responses, the fear-avoidance cycles that keep people stuck, and the thought patterns that amplify pain over time. For adults with CIDP, this means working on the chronic pain, mood, and fatigue burden that persists even when nerve inflammation is controlled.

The program is delivered by trained recovery coaches through live weekly sessions, between-session chat support, and an app with structured learning and practice materials. Modalities include CBT, ACT, somatic tracking, and other mind-body therapies for chronic pain. Coaches are specialized in persistent physical conditions, which means they focus on your CIDP-related pain rather than general mental health.

Lin Health partners with health systems including Mayo Clinic and works with the pain neuroscience research. The approach is rooted in pain neuroscience education and current research on central sensitization and nociplastic pain mechanisms, which can overlap with and amplify CIDP neuropathic pain.

If immunotherapy is managing your nerve inflammation but pain, fatigue, or mood symptoms are still affecting your daily life, a behavioral approach may be worth exploring alongside your current treatment plan.

Lin Health is covered by most major insurance plans in Colorado, Texas, Florida, California, and New York, with coverage in additional states as well. Wait times are short, often with a same-day callback after signup. Check your insurance eligibility.

FAQ

What is CIDP and how is it diagnosed?

CIDP is an autoimmune condition where the immune system attacks the myelin sheath of peripheral nerves, causing progressive weakness and sensory changes. Diagnosis typically involves nerve conduction studies, lumbar puncture for elevated cerebrospinal fluid protein, and clinical evaluation based on the EAN/PNS diagnostic criteria. Symptoms must persist for at least 8 weeks to distinguish CIDP from Guillain-Barre syndrome.

Is CIDP curable?

CIDP is treatable but not currently considered curable. Up to 50% of patients treated with IVIg eventually achieve treatment-free remission, meaning they can stop therapy without relapsing. Others require ongoing maintenance treatment. Early and accurate diagnosis improves outcomes.

What is the first-line treatment for CIDP?

The EAN/PNS guideline recommends IVIg, corticosteroids, and plasma exchange as first-line treatments. IVIg is the most commonly used initial therapy, typically administered at a dose of 2 g/kg. The choice among first-line options depends on the CIDP subtype, patient preference, access, and side-effect profile.

How long does IVIg treatment for CIDP last?

IVIg is usually given as a loading dose followed by maintenance infusions every 3 to 4 weeks. Treatment duration varies. Clinicians attempt gradual dose reductions over time, and roughly half of patients eventually stop treatment without relapse. Others may require IVIg for years.

Can behavioral therapy help with CIDP pain?

CBT and ACT have evidence for reducing chronic pain, disability, and mood symptoms in adults with persistent pain conditions. Since over 60% of CIDP patients report chronic pain and standard immunotherapies do not directly address it, behavioral approaches may help fill this gap as part of a coordinated treatment plan.

What are the newest treatments for CIDP?

Efgartigimod (VYVGART Hytrulo) became the first FDA-approved FcRn inhibitor for CIDP in June 2024. Additional FcRn blockers (nipocalimab, batoclimab) are in late-stage trials. Complement pathway inhibitors and hematopoietic stem cell transplant are also under investigation for refractory cases.

This article is for informational purposes only and is not medical advice. Consult a qualified healthcare provider before making changes to your treatment plan. CIDP management should be guided by a neurologist experienced in inflammatory neuropathies.

Last reviewed: September 2026